ArticleVirchows Archiv : an international journal of pathology2014
Molecular classification of breast cancer.
Article in Virchows Archiv : an international journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk of locoregional recurrence after breast cancer surgery by molecular subtype-a systematic review and network meta-analysis.Irish journal of medical science · 2024Pooled it
- Diabetes Driven Oncogenesis and Anticancer Potential of Repurposed Antidiabetic Drug: A Systemic Review.Cell biochemistry and biophysics · 2024Pooled it
- Spatiotemporal cell type deconvolution leveraging tissue structure.Research square · 2026Article
- Effect of Ageratum fastigiatum on Viability, Migration and Proliferation of Breast Cancer Cells in 2D and 3D Culture Models.Applied biochemistry and biotechnology · 2026Article
- Spatiotemporal cell type deconvolution leveraging tissue structure.bioRxiv : the preprint server for biology · 2026Article
- Breast cancer histopathological image classification based on collaborative multi-domain feature learning.PloS one · 2026Article
- The Roles of STAT3 and STAT5 in Breast Cancer.Cancers · 2025Review
- Identifying and Targeting Key Driver Genes for Collagen Production within the 11q13/14 Breast Cancer Amplicon.Molecular cancer research : MCR · 2025Article
- Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center.Indian journal of surgical oncology · 2025Article
- Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action.Oncology reviews · 2025Review
- Clinical Implications of Breast Cancer Intrinsic Subtypes.Advances in experimental medicine and biology · 2025Review
- FBLN2 is associated with basal cell markers Krt14 and ITGB1 in mouse mammary epithelial cells and has a preferential expression in molecular subtypes of human breast cancer.Breast cancer research and treatment · 2024Article
- Telomerase inhibition in breast cancer and breast cancer stem cells: a brief review.Medical oncology (Northwood, London, England) · 2024Review
- MicroRNAome profiling of breast cancer unveils hsa-miR-5683 as a tumor suppressor microRNA predicting favorable clinical outcome.Cancer cell international · 2024Article
- [Research progress of breast pathology image diagnosis based on deep learning].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2024Review
- Impact of Molecular Profiling on Therapy Management in Breast Cancer.Journal of clinical medicine · 2024Review
- Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine.Current treatment options in oncology · 2024Review
- NDRGs in Breast Cancer: A Review and In Silico Analysis.Cancers · 2024Review
- Mammographic assessment of breast density as a tool for predicting the response to neoadjuvant therapy in breast cancer patients.Medicine and pharmacy reports · 2024Article
- ZDHHC9: a promising therapeutic target for triple-negative breast cancer through immune modulation and immune checkpoint blockade resistance.Discover oncology · 2023Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is a complex, multifaceted disease encompassing a great variety of entities that show considerable variation in clinical, morphological and molecular attributes. Traditional classifications including histological assessment and clinical staging are used to guide patient management. In recent years, there has been exponential progress in molecular analysis with profound implications for our understanding of breast cancer biology and, hence, classification. There are now genome-based frameworks for the molecular categorisation of breast cancer including the development of prognostic and predictive signatures that potentially allow individualisation of treatment. Here we review the current state of the molecular classifications of in situ and invasive breast cancer including special subtypes. Future perspectives are also provided.
Indexed as
Identifiers
24878755What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.